Press releases

* (R) = Regulatory press releases

Nov 29, 2017

(R) Prospectus relating to Cantargia’s rights issue published
Nov 27, 2017

(R) Extraordinary general meeting in Cantargia
Nov 10, 2017

(R) Notice of extraordinary general meeting in Cantargia AB (publ)
Nov 9, 2017

(R) Cantargia: Combined directed issue and fully guaranteed rights issue of 232 MSEK for its expanded clinical program of immuno-oncology antibody CAN04
Nov 8, 2017

(R) Cantargia publishes interim report for third quarter of 2017
Nov 1, 2017

(R) Cantargia announces a new date for the third quarter interim report
Oct 13, 2017

(R) Cantargia announces first patient treated and completed a three weeks safety evaluation period with immuno-oncology antibody CAN04
Oct 6, 2017

(R) Cantargia obtains patent approval in USA for the antibody CAN04 in development for treatment of cancer
Aug 31, 2017

(R) Cantargia obtains patent approval in Europe for the antibody CAN04 in development for treatment of cancer
Aug 23, 2017

(R) Cantargia publishes half year report
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB